Anti-viral Drugs Market – Industry Focused Research Report by 2023


The uptick in research and development financing is foreseen to boost the market share of antiviral drugs in the coming period.

Anti-Viral Drugs Market-Overview

The development of antiviral drugs has gained momentum in the past few decades, with their effectiveness increasing steadily. The pharmaceutical reports are made by Market Research Future, which includes market options for development. By 2022, an income base of USD 62.67 billion is estimated to be attained with a constructive CAGR of 6.9% in the forecast period.

The uptick in research and development financing is foreseen to boost the market share of antiviral drugs in the coming period. Moreover, private investment in creating a strong development pipeline is estimated to enhance the growth of the antiviral drugs market companies in the upcoming period.

Segmental Analysis 

The segmental study of the antiviral drugs market has been conducted on the basis of application, mechanism of action, and regions. Based on the application, the antiviral drugs market comprises of HIV/AIDS, hepatitis, influenza, herpes, and others. On the basis of the mechanism of action, the antiviral drugs market is segmented into reverse transcriptase inhibitors, protease inhibitors, nucleotide polymerase inhibitors, and others. On the basis of regions, the antiviral drugs market has been segmented into the Americas, Africa, Europe, Asia Pacific, and the Middle East.

Detailed Regional Analysis 

The regional examination of the antiviral drugs market includes regional markets such as the Americas, Africa, Europe, Asia Pacific, and the Middle East. The Americas antiviral drugs market is the chief market in the forecast period. The North American region is leading the antiviral drugs market with a segment of more than 30%.  This development is credited to the prevalence of important companies in the region, accessibility of state-of-the-art healthcare substructure, and collective awareness of viral diseases. The European region is the subsequent principal antiviral drug market. Also, the Asia Pacific region is projected to be the fastest mounting region in the antiviral drugs market. The growing patient pool, improving financial stability, and the incidence of sturdy and well-known generic drug markets in South Asian nations are a number of the significant factors estimated to provide the Asia Pacific antiviral drugs market with growth openings.

Competitive Analysis

The enhanced delivery channels are anticipated to generate a novel level in the market by shortening lead times. The market is appraised to return to normal realistically in the upcoming months, with market front runners controlling the charge for transformation. The conditions in the market are assessed to be austere at first but are predicted to recover in the forthcoming years. The advances being generated in the market can encapsulate a large part of the market in the span of the forecast period. This is likely to impact the long term progress of the global market in the future. The technological evolution in the market is estimated to further promote the options for evolution in the forecast period. The emergence of significant trends in this period is likely to define the augmentation of the global market in the upcoming period. The policies established in the different regional markets are projected to spur the market in the approaching period.

The chief contributors in the antiviral drugs market are Gilead Sciences Inc., Merck Co. Inc., Hoffmann-La Roche Ltd., Novartis International AG, GlaxoSmithKline PLC, Abbott Laboratories, Johnson Johnson, AstraZeneca AB, Cipla Inc., and others.

Industry Updates:

Sep 2020 The Supreme Court in India recently stated that there was an endorsement by the Central government on the usage of Remdesivir and Fabiparivir as drugs to treat COVID-19. Favipiravir and Remdesivir are antiviral drugs, and their effectiveness in treating COVID-19 patients has been a subject of debate among medical specialists. Favipiravir was advanced by Fujifilm Toyama Chemical and was essentially approved to treat influenza.




193 Blog posts